07.17.14
A research group at Dokkyo Medical University School of Medicine collaborated with other Japanese health institutions to conduct a double-blind, crossover study to evaluate the effects of NKCP, a purified filtrate of Bacillus subtilis natto culture that is a food-based extract of natto, a traditional Japanese fermented food made from soybean, on blood pressure in individuals with lifestyle-related diseases. In the U.S., NKCP is known by the brand name as BFBP (Bacillopeptidase F Proprietary Blend).
The aim of the study was to investigate the effect of both nattokinase and NKCP, a natto culture filtrate from Daiwa Pharmaceuticals, on blood pressure in patients with lifestyle diseases.
In the study, NKCP and other supplements derived from natto were administered to 21 individuals with lifestyle-related diseases, to evaluate their effects on blood pressure. Study participants health conditions included hypertension, hyperlipidemia and diabetes.
A four-week course of NKCP significantly decreased average systolic blood pressure from 130.9 to 120.5 mmHg (p=0.001) and diastolic blood pressure from 72.9 to 68.6 mmHg (p=0.024). However, after a four-week treatment with nattokinase, no significant changes in systolic or diastolic blood pressure were found (126.8 to 126.4 mmHg, and 70.9 to 68.3 mmHg, respectively).
The difference in the effect on blood pressure between these two substances is considered to be due to the differences of the in vitro experimental results on blood fluidity. The use of dietary supplements, especially NKCP, from natto provides additional blood pressure lowering effects in patients already receiving medical care.
The results, published in Journal of Hypertension: Open Access (2014 3:1), showed significant hypotensive effects in the NKCP treatment group, which was attributed to an improvement in blood fluidity by NKCP. Ongoing research is expected to reveal further wide-range functions for NKCP.
For more information: www.dhdusa.net
The aim of the study was to investigate the effect of both nattokinase and NKCP, a natto culture filtrate from Daiwa Pharmaceuticals, on blood pressure in patients with lifestyle diseases.
In the study, NKCP and other supplements derived from natto were administered to 21 individuals with lifestyle-related diseases, to evaluate their effects on blood pressure. Study participants health conditions included hypertension, hyperlipidemia and diabetes.
A four-week course of NKCP significantly decreased average systolic blood pressure from 130.9 to 120.5 mmHg (p=0.001) and diastolic blood pressure from 72.9 to 68.6 mmHg (p=0.024). However, after a four-week treatment with nattokinase, no significant changes in systolic or diastolic blood pressure were found (126.8 to 126.4 mmHg, and 70.9 to 68.3 mmHg, respectively).
The difference in the effect on blood pressure between these two substances is considered to be due to the differences of the in vitro experimental results on blood fluidity. The use of dietary supplements, especially NKCP, from natto provides additional blood pressure lowering effects in patients already receiving medical care.
The results, published in Journal of Hypertension: Open Access (2014 3:1), showed significant hypotensive effects in the NKCP treatment group, which was attributed to an improvement in blood fluidity by NKCP. Ongoing research is expected to reveal further wide-range functions for NKCP.
For more information: www.dhdusa.net